Addiction Science & Clinical Practice (Nov 2023)

Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods

  • Jane M. Liebschutz,
  • Geetha A. Subramaniam,
  • Rebecca Stone,
  • Noa Appleton,
  • Lillian Gelberg,
  • Travis I. Lovejoy,
  • Amanda M. Bunting,
  • Charles M. Cleland,
  • Karen E. Lasser,
  • Donna Beers,
  • Catherine Abrams,
  • Jennifer McCormack,
  • Gail E. Potter,
  • Ashley Case,
  • Leslie Revoredo,
  • Eve M. Jelstrom,
  • Margaret M. Kline,
  • Li-Tzy Wu,
  • Jennifer McNeely

DOI
https://doi.org/10.1186/s13722-023-00424-8
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Background Preventing progression to moderate or severe opioid use disorder (OUD) among people who exhibit risky opioid use behavior that does not meet criteria for treatment with opioid agonists or antagonists (subthreshold OUD) is poorly understood. The Subthreshold Opioid Use Disorder Prevention (STOP) Trial is designed to study the efficacy of a collaborative care intervention to reduce risky opioid use and to prevent progression to moderate or severe OUD in adult primary care patients with subthreshold OUD. Methods The STOP trial is a cluster randomized controlled trial, randomized at the PCP level, conducted in 5 distinct geographic sites. STOP tests the efficacy of the STOP intervention in comparison to enhanced usual care (EUC) in adult primary care patients with risky opioid use that does not meet criteria for moderate-severe OUD. The STOP intervention consists of (1) a practice-embedded nurse care manager (NCM) who provides patient participant education and supports primary care providers (PCPs) in engaging and monitoring patient-participants; (2) brief advice, delivered to patient participants by their PCP and/or prerecorded video message, about health risks of opioid misuse; and (3) up to 6 sessions of telephone health coaching to motivate and support behavior change. EUC consists of primary care treatment as usual, plus printed overdose prevention educational materials and an educational video on cancer screening. The primary outcome measure is self-reported number of days of risky (illicit or nonmedical) opioid use over 180 days, assessed monthly via text message using items from the Addiction Severity Index and the Current Opioid Misuse Measure. Secondary outcomes assess other substance use, mental health, quality of life, and healthcare utilization as well as PCP prescribing and monitoring behaviors. A mixed effects negative binomial model with a log link will be fit to estimate the difference in means between treatment and control groups using an intent-to-treat population. Discussion Given a growing interest in interventions for the management of patients with risky opioid use, and the need for primary care-based interventions, this study potentially offers a blueprint for a feasible and effective approach to improving outcomes in this population. Trial Registration: Clinicaltrials.gov, identifier NCT04218201, January 6, 2020.

Keywords